We analyzed NSCLC patient data in the IMvigor210 cohort, and we found that patients in the low-risk group responded better to anti-PD-L1 therapy than those in the high-risk group (Figure 5C). The gene discussed is CD274; the disease is non-small cell lung carcinoma.